RE: Optiobiotix22 Dec 2022 09:13
Hi Toyin. Sure. So we are waiting on the details (for more than 2 years) on the details of a licensing deal with Croda.
Now, say Skin want X amount. Croda think "no, too much, Y amount". If sales are string, it gives more leverage to Skin. iF sales are low, flat (or not significantly improving), if I were croda, i would say "well, you want X, but based on what? Look at your dismal sales. It will need our marketing muscle to increase, especially after a poor, I mean "soft" launch. That costs money. So its not worth currently what you are asking. We will offer Y. Take it or leave it? If you leave it, you don't have the resources or management skill to expand this product and penetrate, so it will just wither. Best to take our smaller offer but see the actual pie increase"
No? Dont agree? To put it simply, stronger sales and launch would put skin into a stronger bargaining position. Their position is now weak with Croda.